Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0GI2H)

• Drug Name: PF-07264660 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Atopic dermatitis	EA80	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM0GI2H

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-4 (IL4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexpramipexole	DM6KXAU	Eosinophilic asthma	CB02.0	Phase 3	[3]
SAR-156597	DMUICJD	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[4]
PEGylated pitrakinra	DMBPJ9U	Asthma	CA23	Phase 2	[5]
Tepoxalin	DMVS61L	Asthma	CA23	Phase 2	[6]
Romilkimab	DMYEZ5J	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[7]
IL-4R	DMYEGRH	N. A.	N. A.	Phase 2	[8]
Pascolizumab	DMU3XJP	Asthma	CA23	Phase 2	[5]
PF-07275315	DMHRVUY	Atopic dermatitis	EA80	Phase 1	[2]

Drug(s) Targeting Interleukin-33 (IL33)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tozorakimab	DMCXN80	Acute respiratory failure	CB41.0	Phase 3	[9]
SAR440340	DMKYXSS	Chronic obstructive pulmonary disease	CA22	Phase 3	[10]
Itepekimab	DMR8NDD	Chronic obstructive pulmonary disease	CA22	Phase 3	[10]
MEDI3506	DMDI7SA	Chronic obstructive pulmonary disease	CA22	Phase 3	[11]
AMG 282	DM92YWD	Asthma	CA23	Phase 1	[12]

Drug(s) Targeting Interleukin-13 (IL13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tralokinumab	DM6ENSJ	Atopic dermatitis	EA80	Approved	[13]
Lebrikizumab	DMQP0X5	Severe asthma	CA23	Phase 3	[5]
Dexpramipexole	DM6KXAU	Eosinophilic asthma	CB02.0	Phase 3	[3]
Cendakimab	DM9LSBJ	Eosinophilic esophagitis	DA24.1	Phase 3	[14]
SAR-156597	DMUICJD	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[4]
PEGylated pitrakinra	DMBPJ9U	Asthma	CA23	Phase 2	[5]
Romilkimab	DMYEZ5J	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[7]
QAX-576	DMUWFI7	Allergic rhinitis	CA08.0	Phase 2	[15]
Anrukinzumab	DMTG2O0	Asthma	CA23	Phase 2	[16]
Dectrekumab	DM1H7UK	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-13 (IL13)	TT0GVCH	IL13_HUMAN	Not Available	[2]
Interleukin-33 (IL33)	TT5MD4P	IL33_HUMAN	Not Available	[2]
Interleukin-4 (IL4)	TTLGTKB	IL4_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT05496738) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07264660 IN HEALTHY PARTICIPANTS. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Pfizer
• [3] Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019 Jun;46:29-33.
• [4] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [5] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [6] Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Behring Inst Mitt. 1995 Jun;(96):118-30.
• [7] A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
• [8] Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001 Jun;107(6):963-70.
• [9] ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jul 31;21(1):691.
• [10] Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668.
• [11] ClinicalTrials.gov (NCT05742802) A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations. U.S.National Institutes of Health.
• [12] Clinical pipeline report, company report or official report of Amgen.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023 Jan;130(1):21-27.
• [15] Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
• [16] Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900.